- Home
- FBRX vs SPRO Comparison
FBRX vs SPRO Comparison
Compare FBRX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- SPRO
- Stock Information
- Founded
- FBRX N/A
- SPRO 2013
- Country
- FBRX United States
- SPRO United States
- Employees
- FBRX N/A
- SPRO N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- SPRO Health Care
- Exchange
- FBRX Nasdaq
- SPRO Nasdaq
- Market Cap
- FBRX 154.5M
- SPRO 162.1M
- IPO Year
- FBRX N/A
- SPRO 2017
- Fundamental
- Price
- FBRX $11.60
- SPRO $2.33
- Analyst Decision
- FBRX Strong Buy
- SPRO Buy
- Analyst Count
- FBRX 2
- SPRO 4
- Target Price
- FBRX $61.00
- SPRO $5.00
- AVG Volume (30 Days)
- FBRX 73.6K
- SPRO 890.8K
- Earning Date
- FBRX 08-13-2025
- SPRO 08-04-2025
- Dividend Yield
- FBRX N/A
- SPRO N/A
- EPS Growth
- FBRX N/A
- SPRO N/A
- EPS
- FBRX N/A
- SPRO N/A
- Revenue
- FBRX N/A
- SPRO $44,584,000.00
- Revenue This Year
- FBRX N/A
- SPRO N/A
- Revenue Next Year
- FBRX N/A
- SPRO N/A
- P/E Ratio
- FBRX N/A
- SPRO N/A
- Revenue Growth
- FBRX N/A
- SPRO N/A
- 52 Week Low
- FBRX $4.11
- SPRO $0.51
- 52 Week High
- FBRX $28.68
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- FBRX 53.91
- SPRO 38.82
- Support Level
- FBRX $10.02
- SPRO $2.30
- Resistance Level
- FBRX $10.99
- SPRO $2.45
- Average True Range (ATR)
- FBRX 0.86
- SPRO 0.14
- MACD
- FBRX -0.06
- SPRO -0.08
- Stochastic Oscillator
- FBRX 60.78
- SPRO 3.26
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.